Objective: The purpose of this study was to prospectively test the null hypothesis that there is no difference in the clinical effectiveness of azithromycin and erythromycin for the treatment of chlamydia cervicitis in pregnancy. 
lation, z Azithromycin has several potential advantages that affect compliance including a single-dose regimen and a much lower rate of side effects.
The purpose of this study was to determine the effectiveness of a single dose of azithromycin in comparison with the standard 7-day erythromycin treatment regimen for chlamydia cervicitis during pregnancy.
SUBJECTS AND METHODS
The reported study is a prospective randomized trial of azithromycin vs. erythromycin for the treatment of chlamydia cervicitis in pregnancy. The research protocol was approved by the Institutional Review Board of the Medical University of South Carolina.
Routine screening for chlamydia cervicitis and gonorrhea was performed on all antepartum patients at their first prenatal visit and again in the third trimester (32-36 weeks gestation). All pregnant women over the age of 15 years who tested positive for Chlamydia trachomatis by DNA hybridization (Gen-Probe Pace, San Diego, CA) from a cervical swab specimen were eligible for enrollment. The only exclusion to enrollment was an allergy to The two treatment groups were similar with respect to age, race, gravidity, and parity (Table 1) . Unexpectedly, a difference of 8.2 weeks in gestational age was found between the two treatment groups (erythromycin 28.6 weeks; azithromycin 20.4 weeks; P 0.002).
Perinatal outcome was not different between the two groups. The mean gestational ages at birth were 38.8 +_ 1.6 and 38.0 _+ 2.0 weeks for the azithromycin and erythromycin groups, respectively. In the azithromycin group, there were 6 (9.2%) preterm deliveries (<37 weeks) of which 3 were due to preterm premature rupture of the membranes (PROM). In the erythromycin group, there were 8 (12.3%) preterm deliveries of which 5 were due to preterm PROM. There were no stillbirths, neona- Azithromycin is the prototype of a new class of antibiotics, the azilides. They have been shown to be as efficacious as doxycycline for the treatment of chlamydia cervicitis in nonpregnant women, z This was demonstrated with a single-star g dose of azithromycin compared to a standard 7-day doxycycline regimen of 100 mg twice a day. On reculture, 98% of women in both groups were free of disease, z In a single small investigation, the efficacy of azithromycin and erythromycin was compared in 30 pregnant women with cervical chlamydial infection. 9 Despite a high rate of gastrointestinal side effects in the subjects receiving erythromycin, there was no difference in efficacy between the two groups. Unfortunately, the small sample size prevented the investigation from having adequate power to discriminate between the two treatment regimens.
Azithromycin is closely related to erythromycin, although its pharmacokinetics differ greatly. Azithromycin differs from erythromycin due to an insertion of a methyl-substituted nitrogen atom into the aglycone ring. This insertion allows for rapid intracellular transfer which potentially makes it more effective against chlamydia, which is an obligate intracellular parasite. Erythromycin has less effective intracellular penetrance and therefore relies more heavily on eradication of the organism during the transient extracellular portion of chla- 
